Tiny Biotech Stock Set to Go Higher with Cure for Something Other Than Cancer

 

Dynamic Wealth Report | January 20, 2016 Discover Great Penny Stocks…   Check out a secret strategy to uncover all-star penny stocks!    Everything you need is right here… Tiny Biotech Stock Set To Go Higher With Cure For Something Other Than Cancer By Brad Hartung, Penny Stock Research Traditionally, biotech investors are handsomely rewarded for owning shares of companies working on treatments for cancer, once approved by the FDA.  Yet there is one company poised to skyrocket on a drug that cures a non-cancerous ailment. Sophiris Bio (SPHS, $1.67) is knocking on the door of an effective treatment for enlarged prostate.   Located in one of the most beautiful places on earth, La Jolla, California, SPHS announced in November that a study of its drug, PRX302, had met its goal.  What was the goal?  According to the company, their drug had, "significantly improved symptoms in men suffering from enlarged prostate."  That does not sound exciting or significant but it caused the share price to triple in just a matter of days.  The real news is that the drug did not harm the patient which is the main reason for Phase I and II testing.    Since then, the price has backed off those dizzying highs in anticipation of more detailed reports in early and mid-year 2016.  Investors and the company are looking for a successful Phase III test that mirrors the results of the Phase II test.  SPHS is hoping that that consistency will pave the way toward FDA approval.  This is a big 'if' because the company, according to their 3Q results, only has enough money to continue operating until April.  Everything hinges on SPHS's ability to raise enough money to fund a successful Phase III test.   This is where investing becomes speculating.  SPHS estimates the market for treating enlarged prostate is in the neighborhood of $1 billion, so the potential for SPHS to make a lot of money when their drug is approved is very high.  But when you look at the details in the recent Phase II test results, SPHS states that their drug did not significantly increase urine flow, one of the main symptoms of enlarged prostate.  So, what you may have is a one-hit wonder that does not really perform much better than a placebo.   In other words, investing in SPHS isn't necessarily the most logical choice.  You cannot point to A and then B and then expect to get C.  SPHS does not have a safety net or a pipeline of drugs in development. It could all fall apart if SPHS cannot get the money it needs.  (That is hard to imagine since they could probably find people with that much money sitting in a La Jolla Starbucks right now.)   However, this is the magic of biotech.  For just a few million dollars, SPHS can fund a Phase III test that, if successful, can garner FDA approval - which would send the stock price into the stratosphere.  On the surface, it does not make sense that SPHS will be a hit.  But, with markets crashing around the world this year, SPHS has held its value really well and that may be the best indicator of all.   Regards,   Brad Hartung   BIO:  Brad Hartung writes the Small Cap Pirate blog and is the editor of the soon to be released Left Coast Speculator. Do You Trade Options?   Learn the powerful benefits of options trading here… Copyright 2016 Hyperion Financial Group, LLC. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This email may only be used pursuant to the subscription agreement controlling use of the Dynamic Wealth Report website and any reproduction, copying, or redistribution of this email or its contents, in whole or in part, is strictly prohibited without the express written permission of Hyperion Financial Group, LLC. If you purchase anything through a link in one of our emails or from a link on our website, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. LEGAL DISCLAIMER: Neither Hyperion Financial Group LLC nor any of it's employees, contractors or officers are registered investment advisors or a Broker/Dealer. As such, Hyperion Financial Group, LLC does not offer or provide personalized investment help. Although Hyperion Financial Group, LLC employees and contractors may answer general customer service questions, they are not licensed under securities laws to address your particular investment situation. Nothing in this report, nor any communication by our employees or contractors to you should be considered personalized investment help. Owners and writers may have positions in the securities that are discussed. However, no associated employees or contractors may intentionally engage in any transaction that directly or indirectly competes with the interests of our subscribers. We accept no compensation from any companies mentioned in our reports. Past performance is no guarantee of future results. All information is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell any security. All opinions, analyses and information contained herein are based on sources believed to be reliable and written in good faith, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. Investments recommended in this publication should only be made after consulting with your financial advisor.

 

This message was sent to ignoble.experiment@arconati.us from: Dynamic Wealth Report | customerservice@hyperionfinancial.com | Hyperion Financial | 20701 N Scottsdale Rd, Ste 107-154 | Scottsdale, AZ 85255

Email Marketing by

Manage Your Subscription